Market News AIOpen the app

Novo Nordisk shared new trial results showing CagriSema helps with weight loss and reduces food cravings before the FDA's decision.

ResultsRead the original at Benzinga
Good for NVO

Novo Nordisk reported about 21% weight loss with lower CagriSema doses, versus 2% with placebo, plus fewer food-related thoughts among Wegovy users. This supports its drug business, but CagriSema remains unapproved and its safety and effectiveness are not established.

NVO · Novo Nordisk

AI read · Good for NVO

The AI's read

The findings add evidence that CagriSema may help people lose weight, alongside reports of fewer food-related thoughts among Wegovy users. This supports Novo Nordisk’s obesity drug business. CagriSema still awaits a U.S. decision, and trials have not established its safety and effectiveness.

Get alerts for NVO

Follow Novo Nordisk (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVO
Free on the App Store and Google Play, or on the web.